Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
Minimalist illustration of T cell engager and antibody-drug conjugate

Jul 13, 2026

AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline

Ardigen and VERAXA Biotech have announced a collaboration aimed at enhancing drug discovery through AI technologies, specifically targeting cancer therapies.This partnership will leverage Ardigen's expertise in AI and computational biology to support VERAXA's BiTAC pipeline, which focuses on T cell engagers (TCEs) and antibody-drug conjugates (ADCs). By utilizing AI-enabled tools, the collaboration aims to optimize the selection of cancer target pairs, thereby improving therapeutic designs while
Minimalist illustration of tumor-associated antigens

Jul 13, 2026

Veraxa Uses AI to Advance BiTAC Pipeline

Veraxa Biotech AG has partnered with Ardigen S.A. to leverage AI in enhancing its BiTAC pipeline, which focuses on bispecific T cell engagers and antibody-drug conjugates. This collaboration aims to develop computational tools for selecting synergistic cancer target combinations that fit Veraxa’s innovative therapeutic architecture.The BiTAC platform features a unique mechanism where a T cell engager or ADC is divided into two inactive precursor molecules. These reconstitute a functional agent o
A colorful molecule model on a lab bench surrounded by equipment.

Jul 13, 2026

Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Insilico Medicine has expanded its collaboration with China Medical System Holdings (CMS) to enhance AI-driven drug discovery for central nervous system (CNS) conditions. This partnership builds on a previous agreement established three months prior.The new collaboration focuses on a unique mechanism of action discovered through Insilico's PandaOmics platform, which is integral to its Pharma.ai suite that includes tools for molecule generation and trial outcome predictions. Under this deal, Insi
Minimalist illustration of T cell engager and antibody-drug conjugate

Jul 13, 2026

AI partnership aims to sharpen cancer target selection at VERAXA

VERAXA Biotech has announced a collaboration with Ardigen to enhance its cancer therapy pipeline through AI-driven drug discovery.This partnership aims to optimize the selection of cancer target pairs for VERAXA’s BiTAC® platform, which focuses on conditionally active T cell engagers (TCEs) and antibody-drug conjugates (ADCs). By leveraging Ardigen's AI capabilities, VERAXA intends to improve the identification of synergistic target combinations, potentially increasing the success rates of its d
A vial of a drug compound on a lab bench in a dimly lit laboratory.

Jul 13, 2026

VERAXA Biotech AG Announces AI Collaboration with Ardigen to Support BiTAC Cancer Therapeutics Pipeline

VERAXA Biotech AG has entered a collaboration with Ardigen to enhance its BiTAC cancer therapeutics pipeline through AI-driven strategies.On July 13, 2026, VERAXA Biotech AG announced its partnership with Ardigen S.A., an AI-focused company known for its contributions to precision medicine. This collaboration aims to advance VERAXA's BiTAC® pipeline, which includes T cell engagers (TCEs) and antibody drug conjugates (ADCs). A central aspect of this partnership is the integration of AI to improve
A drug compound vial on a lab table with a research notebook

Jul 13, 2026

Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

Insilico Medicine and China Medical System (CMS) have expanded their collaboration to enhance AI-driven drug discovery in central nervous system (CNS) diseases. This partnership builds on their previous agreement, focusing on a mass-market indication with a novel mechanism of action identified through Insilico's PandaOmics platform.The collaboration aims to leverage Insilico's advanced AI capabilities in drug discovery alongside CMS's robust R&D expertise and commercialization strategies. Insili
Flat illustration of RNA and DNA structures

Jul 13, 2026

Syngenis banks $4M pre-float to power AI-driven biotech platform

Syngenis Labs has successfully raised $4 million in a pre-float funding round aimed at advancing its AI-driven biotech platform, which focuses on RNA and DNA-based medicines. This funding will enable the Perth-based company to enhance its capabilities and position itself within the burgeoning genetic medicine sector in Australia.The funding round, which saw strong interest from investors, is intended to support the development of Syngenis' integrated ecosystem for RNA and DNA therapeutics. The c
A minimalist illustration of a pill and a molecule on a solid background.

Jul 11, 2026

Takeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?

Takeda Pharmaceutical has recently partnered with Insilico Medicine’s Pharma.AI platform, enhancing its drug discovery capabilities through artificial intelligence. This collaboration comes as the company experiences a notable rise in its stock price, reflecting investor optimism about its future prospects.Year-to-date, Takeda's shares have increased by 8.5%, and the company has achieved a total shareholder return of 26.82% over the past year. However, there has been a slight decline of 6.94% in
Petri dish with cultured cells in a dimly lit lab

Jul 10, 2026

Insilico Medicine to Present Longevity and AI Drug Innovations at BIO Asia-Taiwan 2026

Insilico Medicine is poised to make a significant impact at BIO Asia-Taiwan 2026, where CEO Dr. Alex Zhavoronkov will deliver a keynote on the intersection of longevity science and artificial intelligence. Scheduled for July 15, his presentation will explore how these disciplines can transform drug discovery and enhance company scalability.The conference, running from July 15 to 19 at the Taipei Nangang Exhibition Center, will feature over 850 exhibitors from nearly 60 countries, focusing on adv
A minimalist illustration of a pill on a dark background, symbolizing an oral medication.

Jul 10, 2026

Chinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RA

Chinese biotech MindRank has successfully secured $52 million to enhance its AI-driven pipeline, focusing on an oral GLP-1 receptor agonist currently in Phase III trials in China.Based in Hangzhou, MindRank utilizes its innovative Molecule Arts Platform (MAP), which integrates computational methods, experimental data, and clinical insights to streamline drug discovery. This funding will support the development of its lead candidate, MDR-001, aimed at treating obesity and type 2 diabetes. The com
A test tube in a dimly lit lab, symbolizing antibody research.

Jul 9, 2026

Alchemab Raises £25 Million Extension to Series A to Advance AI-Driven Antibody Pipeline

Alchemab Therapeutics has successfully secured a £25 million extension to its Series A funding, bringing its total to £109 million, marking a significant milestone as the largest life sciences investment from the British Business Bank to date.This new capital will facilitate the growth of Alchemab's clinical pipeline and expand its proprietary antibody database from 500 million to over one billion sequences. The company employs its AI-driven Resiliome™ platform to discover naturally occurring pr
A minimalist representation of a drug compound in flat design.

Jul 9, 2026

AI in pharma market to hit $28.6b by 2034 on drug discovery push

The global market for artificial intelligence in pharmaceuticals is projected to reach $28.63 billion by 2034, primarily fueled by advancements in drug discovery processes.According to a report by Polaris Market Research, AI is increasingly integral to various stages of drug discovery, including identifying drug targets, analyzing protein structures, and simulating chemical interactions, which surpasses traditional laboratory methods. The financial implications of this shift are substantial, as